I reread Charlie's article tonight and I had overlooked some information.
https://themedicinemaker.com/manufacture/eliminating-bioconjugation-roadblocksvaccine and drug development !!! Derek said we were only involved in vaccine quality control?
"Confidence in such
bioconjugation tools can also be derived from the growing catalog of diagnostic and therapeutic R&D efforts that have been made possible by these novel binding technologies.
Adiponectin immunosensor development, tumor cell isolation, and extracellular vesicle research are just a few examples of the research areas benefiting from this approach. "
we have been working on these for a while and have publication on all 3 on our webpage.
https://www.anteotech.com/life-science/anteobind/publications/why I revisited the article was because I saw this from Merck
Antibody-drug
conjugates (ADCs) are an
emerging class of medicines designed for high-specificity targeting and destruction of cancer cells while preserving healthy cells.
https://www.linkedin.com/posts/merc...ugates-adcs-activity-6807939340547715072-41jKthen reading the article we have this
"A recent study used the technology to conjugate recombinant Spike RBD of selected SARS-CoV-2 variants. It sought to understand the impact of COVID-19 vaccination on the levels of neutralizing antibodies against these RBD variants, and demonstrated that the nanosized molecular glue approach to bioconjugation provides a rapid and effective tool for SARS-CoV-2 multiplex immunoassay development for vaccine study (1)."
from the study
https://www.medrxiv.org/content/10.1101/2021.03.08.21252958v1"The SARS-CoV-2 pandemic virus is consistently evolving with mutations within the receptor binding domain (RBD)
1 being of particular concern
2-4. To date, there is little research into protection offered following vaccination or infection against RBD mutants in emerging variants of concern (UK
3, South African
5, Mink
6 and Southern California
7). To investigate this, serum and saliva samples were obtained from groups of vaccinated (Pfizer BNT-162b2
8), infected and uninfected individuals."
Bead couplingCoupling of RBD mutant antigens was done by
Anteo coupling (#A-LMPAKMM-10, Anteo Tech Reagents) following the manufacturer’s instructions. Briefly, 100 μL of spectrally distinct populations of MagPlex beads (1.25×10
6) (Luminex) were activated in 100 μL of
AnteoBind Activation Reagent for 1 hour at room temperature.
I think management are involved in a lot of projects that we will be hearing about!!! we aren't just relying on our covid test. add batteries, contract services, raw materials ,drug and vaccine development to a growing list of future revenue possibilities.....
